Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (101-110 of 194) with videos related to

Pageof 20
Sort By:
Blood|October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen, Siqing Wang, Yiming Zhou, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
Blood|July 2, 2003
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patientsObiageli N Onwuazor, Xiao-Yan Wen, Ding-Yan Wang, et al.
Nature Genetics|December 28, 1999
Leukaemia disease genes: large-scale cloning and pathway predictionsJ Li, H Shen, K L Himmel, et al.
Marine Pollution Bulletin|July 6, 2004
Entanglement of Australian sea lions and New Zealand fur seals in lost fishing gear and other marine debris before and after Government and industry attempts to reduce the problemBrad Page, Jane McKenzie, Rebecca McIntosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myelomaAriel Anguiano, Sascha A Tuchman, Chaitanya Acharya, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Genes, Chromosomes & Cancer|July 30, 2015
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpressionErming Tian, Magne Børset, Jeffrey R Sawyer, et al.
Molecular Endocrinology (Baltimore, Md.)|October 28, 2006
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formationGregory A Clines, Khalid S Mohammad, Yongde Bao, et al.
Pageof 20

Showing results (101-110 of 194) with videos related to

Sort By:
Pageof 20
Blood|October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen, Siqing Wang, Yiming Zhou, et al.
Blood|June 12, 2009
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocolsAntje Hoering, John Crowley, John D Shaughnessy, et al.
Blood|July 2, 2003
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patientsObiageli N Onwuazor, Xiao-Yan Wen, Ding-Yan Wang, et al.
Nature Genetics|December 28, 1999
Leukaemia disease genes: large-scale cloning and pathway predictionsJ Li, H Shen, K L Himmel, et al.
Marine Pollution Bulletin|July 6, 2004
Entanglement of Australian sea lions and New Zealand fur seals in lost fishing gear and other marine debris before and after Government and industry attempts to reduce the problemBrad Page, Jane McKenzie, Rebecca McIntosh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myelomaAriel Anguiano, Sascha A Tuchman, Chaitanya Acharya, et al.
Blood|May 27, 2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee, Jackie Szymonifka, Elias Anaissie, et al.
British Journal of Haematology|August 26, 2009
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy, Yiming Zhou, Jeff Haessler, et al.
Genes, Chromosomes & Cancer|July 30, 2015
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpressionErming Tian, Magne Børset, Jeffrey R Sawyer, et al.
Molecular Endocrinology (Baltimore, Md.)|October 28, 2006
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formationGregory A Clines, Khalid S Mohammad, Yongde Bao, et al.
Pageof 20